Repligen
RGEN
Repligen (RGEN) - Total liabilities
Total liabilities on the balance sheet as of March 2024 : $0.87 B
According to Repligen 's latest financial reports the company's total liabilities are $0.87 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Repligen - Total liabilities on balance sheet (from 2001 to 2024)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2023-12-31 | $0.85 B | 38.97% |
| 2022-12-31 | $0.61 B | 0.93% |
| 2021-12-31 | $0.60 B | 62.76% |
| 2020-12-31 | $0.37 B | 9.81% |
| 2019-12-31 | $0.34 B | 113.98% |
| 2018-12-31 | $0.15 B | 4.66% |
| 2017-12-31 | $0.15 B | 26.49% |
| 2016-12-31 | $0.12 B | 411.51% |
| 2015-12-31 | $23.48 M | 41.83% |
| 2014-12-31 | $16.56 M | 12.21% |
| 2013-12-31 | $14.75 M | 14.54% |
| 2012-12-31 | $12.88 M | |
| 2011-03-31 | $5.2 M | -1.74% |
| 2010-03-31 | $5.29 M | 14.43% |
| 2009-03-31 | $4.63 M | -2.15% |
| 2008-03-31 | $4.73 M | 33.79% |
| 2007-03-31 | $3.53 M | 11.73% |
| 2006-03-31 | $3.16 M | -4.56% |
| 2005-03-31 | $3.31 M | 35.36% |
| 2004-03-31 | $2.45 M | 9.25% |
| 2003-03-31 | $2.24 M | -15.88% |
| 2002-03-31 | $2.66 M | 112.18% |
| 2001-03-31 | $1.25 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $137.21 B | 15,516.02% | 🇺🇸 USA |
 Thermo Fisher Scientific TMO | $51.88 B | 5,804.85% | 🇺🇸 USA |
 General Electric GE | $132.83 B | 15,018.22% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $82.48 B | 9,287.28% | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | $82.43 M | -90.62% | 🇺🇸 USA |
 Novavax NVAX | $2.51 B | 186.16% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | $1.08 B | 23.63% | 🇺🇸 USA |
 Bio-Techne TECH | $0.76 B | -12.69% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | $1.79 B | 104.73% | 🇺🇸 USA |
 Charles River Laboratories
CRL | $4.53 B | 416.24% | 🇺🇸 USA |